The US Food and Drug Administration (FDA) has approved expanded sizes of the Lutonix 018 drug-coated balloon (DCB) to treat long superficial femoral artery lesions in patients with peripheral arterial disease.
According to a press release, the Lutonix 018 DCB provides clinicians with a variety of longer sizes allowing more options for 7mm diameter vessels. This includes four new lengths: 80mm, 100mm, 150mm and 220mm. The Lutonix 018 DCB is designed to perform over small guidewires, reduce guidewire exchanges and enable alterative access sites.
Lutonix 018 DCB is available in the USA, and is currently undergoing the regulatory approval process in Europe.
Source VascularNews
Duc Tin clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389